Immunotherapy News and Research

Latest Immunotherapy News and Research

Proximity Ligation Assay helps detect effectiveness of cancer vaccines

Cancer vaccines are designed to turn the body's own immune system specifically against tumor cells. Particularly promising are vaccines that are directed against so-called neoantigens: These are proteins that have undergone a genetic mutation in tumor cells and, therefore, differ from their counterparts in healthy cells.

20 Feb 2015

Study results pave way for new clinical trial for glioblastoma patients

Immune cells engineered to seek out and attack a type of deadly brain cancer were found to be both safe and effective at controlling tumor growth in mice that were treated with these modified cells, according to a study published in Science Translational Medicine by a team from the Perelman School of Medicine at the University of Pennsylvania and the Novartis Institutes for BioMedical Research.

19 Feb 2015

New NIH grant to support development of rapid method for diagnosing mucormycosis

Speed is essential in treating deadly mucormycosis fungal infections, but a quick diagnosis is difficult because no routine blood test exists.

19 Feb 2015

NYU Langone, Technion collaborate to advance cancer research

In a groundbreaking step forward to advance global collaboration in the fight against cancer, two of the world's preeminent academic and research institutions -- NYU Langone Medical Center and the Technion-Israel Institute of Technology -- formally announced a $9 million gift from philanthropists Laura and Isaac Perlmutter that will fund two major, joint research endeavors with potentially far-reaching impact in advancing cancer research.

19 Feb 2015

FDA advisory committees to review Amgen's talimogene laherparepvec for metastatic melanoma treatment

Amgen announced today that the Cellular, Tissue and Gene Therapies Advisory Committee and the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration will jointly review the Company's Biologics License Application (BLA) for talimogene laherparepvec.

11 Feb 2015

Discovery improves understanding of factors that trigger allergic asthma

When the mucosal surfaces in the lungs of healthy people come into contact with allergenic substances, so-called regulatory T cells also known as Treg cells, are activated. These are capable of actively preventing the development of allergies.

9 Feb 2015

Crown Bioscience, NRCMM partner to develop new immune-oncology experimental cancer models

Crown Bioscience, Inc., a leading global drug discovery and development service company with its R&D centers across the globe has announced that a new partnership agreement has been reached with the National Resource Center for Mutant Mice and its commercial branch Nanjing Biotech Innovation Corporation, in Nanjing, Jiangsu Province, China.

6 Feb 2015

RXi closes exclusive global license agreement with Hapten Pharmaceuticals for Samcyprone

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering and developing innovative therapies addressing high-unmet medical needs, today announced the closing of its previously disclosed exclusive global license agreement for the therapeutic use of Samcyprone with Hapten Pharmaceuticals, LLC.

5 Feb 2015

Scientists investigate how T cells in colorectal tumors actively fight cancer

In recent years, a standard follow-up to colorectal cancer surgery has been to analyze the tumor tissue for the presence of immune cells. Finding high quantities of cytotoxic T cells, or "killer cells", means that there is a good chance that the disease will take a favorable course and that the risk of metastasis is comparatively low.

5 Feb 2015

Research findings demonstrate new approach to transform behavior of tumor cells

Inserting a specific strain of bacteria into the microenvironment of aggressive ovarian cancer transforms the behavior of tumor cells from suppression to immunostimulation, researchers at Norris Cotton Cancer Center and the Geisel School of Medicine at Dartmouth have found.

5 Feb 2015

BioMed Realty Trust expands footprint in Seattle's core innovation district of South Lake Union

BioMed Realty Trust, Inc. today announced that it is under contract to acquire the 307 Westlake Avenue North building in the heart of the burgeoning South Lake Union life science market of Seattle, Washington for approximately $90 million.

4 Feb 2015

Anti-viral immune cells could inhibit bone marrow transplant infections caused by CMV

Bone marrow transplantation is a life-saving therapy for patients with blood cancers like leukemia or lymphoma. However, the depletion of the patient's immune system prior to transplantation can put patients at risk of for an infection by a virus called cytomegalovirus (CMV) that can be life threatening in these immune-compromised individuals.

4 Feb 2015

Experts recommend sublingual immunotherapy for treatment of allergic rhinitis

Sublingual immunotherapy is one of several state-of-the-science treatments for allergic rhinitis, or "hay fever," being recommended by a panel of experts in a new guideline published Feb. 2, 2015, by the American Academy of Otolaryngology--Head and Neck Surgery Foundation.

3 Feb 2015

MD Anderson and AstraZeneca to conduct multiple studies in ovarian, gynecologic cancers

The University of Texas MD Anderson Cancer Center and AstraZeneca today announced a multiyear strategic research collaboration to conduct multiple, parallel clinical and clinically related studies in ovarian and other gynecologic cancers with the aim of improving patient outcomes.

31 Jan 2015

Blood tests for Chikungunya virus and rheumatoid arthritis could produce similar results

A mosquito-borne virus that has spread to the Caribbean and Central and South America and has caused isolated infections in Florida often causes joint pain and swelling similar to that seen in patients with rheumatoid arthritis.

31 Jan 2015

TxCell receives milestone payment of EUR 1 million concerning Ovasave collaboration, license agreement from Trizell

TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T-cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today the receipt of the latest milestone payment of EUR 1 million from the Ovasave collaboration option, development and license agreement from Trizell (Trizell Holding SA).

30 Jan 2015

Immunotherapy expert discusses the concept of precision immunology and personalized medicine

With President Obama's recent State of the Union speech addressing the launch of a national precision medicine initiative to further tackle cancer and other diseases, a leading immunotherapy expert from Rutgers Cancer Institute of New Jersey weighs in on where we stand with precision immunology and personalized medicine and what needs to be accomplished.

30 Jan 2015

SCCA's Fred Hutch Bone Marrow Transplant Program achieves higher survival rates

The Fred Hutchinson Cancer Research Center Bone Marrow Transplant Program at Seattle Cancer Care Alliance was recently recognized for outperforming its anticipated one-year survival rate for allogeneic transplant patients.

28 Jan 2015

Bpifrance awards TxCell EUR 1.7 million grant for clinical development of Ovasave

27 Jan 2015

TxCell to highlight success factors in cell therapy research at Cell & Gene Therapy Forum 2015

TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Dr. Miguel Forte, Sr. VP Clinical Development and Regulatory Affairs, TxCell, will present at the Cell & Gene Therapy Forum 2015, January 26 - 28, 2015 at Grand Hayatt in Washington DC, United States.

23 Jan 2015

Immunotherapy News and Research

Latest Immunotherapy News and Research

Proximity Ligation Assay helps detect effectiveness of cancer vaccines

Study results pave way for new clinical trial for glioblastoma patients

New NIH grant to support development of rapid method for diagnosing mucormycosis

NYU Langone, Technion collaborate to advance cancer research

FDA advisory committees to review Amgen's talimogene laherparepvec for metastatic melanoma treatment

Discovery improves understanding of factors that trigger allergic asthma

Crown Bioscience, NRCMM partner to develop new immune-oncology experimental cancer models

RXi closes exclusive global license agreement with Hapten Pharmaceuticals for Samcyprone

Scientists investigate how T cells in colorectal tumors actively fight cancer

Research findings demonstrate new approach to transform behavior of tumor cells

BioMed Realty Trust expands footprint in Seattle's core innovation district of South Lake Union

Anti-viral immune cells could inhibit bone marrow transplant infections caused by CMV

Experts recommend sublingual immunotherapy for treatment of allergic rhinitis

MD Anderson and AstraZeneca to conduct multiple studies in ovarian, gynecologic cancers

Blood tests for Chikungunya virus and rheumatoid arthritis could produce similar results

TxCell receives milestone payment of EUR 1 million concerning Ovasave collaboration, license agreement from Trizell

Immunotherapy expert discusses the concept of precision immunology and personalized medicine

SCCA's Fred Hutch Bone Marrow Transplant Program achieves higher survival rates

Bpifrance awards TxCell EUR 1.7 million grant for clinical development of Ovasave

TxCell to highlight success factors in cell therapy research at Cell & Gene Therapy Forum 2015

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Immunotherapy News and Research

Latest Immunotherapy News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in